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Open issues on DAPT: preloading, optimal length of treatment, the role of extended DAPT
Current trends in dual antiplatelet 
therapy: a 2017 update
Luigi Biasco, Giulia Montrasio, Marco Moccetti, Giovanni Pedrazzini
Fondazione Cardiocentro Ticino, Division of Cardiology, Lugano, Switzerland
Introduction
Platelet inhibition represents the cornerstone of 
cardio vascular therapy, owing to the central role of 
platelets in the genesis of acute ischaemic events. Dual 
antiplatelet therapy (DAPT) addresses two main path-
ways of platelet activation: inhibition of cyclo-oxyge-
nase-mediated thromboxane A2 formation by aspirin; 
and inhibition of the ADP-activated surface receptor 
P2Y12 by means of a family of drugs including cangre-
lor, clopidogrel, prasugrel, ticagrelor and ticlopidine 
(fig. 1).
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Summary
Platelet inhibition represents the cornerstone of cardiovascular therapy, 
 owing to the central role of platelets in the genesis of acute ischaemic 
events. The aim of this article is to review current evidence and trends in cor-
onary dual antiplatelet therapy (DAPT), such as preloading in patients with 
an acute coronary syndrome, optimal duration of DAPT after stent implanta-
tion and indications for long-term treatment, to provide an overview on the 
role of DAPT following percutaneous valve and structural interventions, and 
an update on the most recent information concerning the concomitant use 
of DAPT and oral anticoagulation. A short glance into future perspectives 
and trends in DAPT will be given.
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Even though much is known about the efficacy and 
safety of DAPT, as reflected by the most recent interna-
tional guidelines [1–3], some specific issues are a mat-
ter of ongoing discussion. The aim of this review is to 
give a concise overview of current knowledge on this 
topic and to discuss some open issues, such as preload-
ing in patients with an acute coronary syndrome (ACS), 
which aims to prepare the lesion in view of the immi-
nent percutaneous treatment, the optimal duration of 
DAPT after stent implantation, defined at the shortest 
period necessary to protect the stent against the risk of 
early and late stent thrombosis, and, finally, the long-
term treatment (more than 12 months) recently consid-
ered as a potential alternative in patients at very high 
ischaemic risk (fig. 2). A final glimpse of new concepts, 
upcoming studies and applications of DAPT after valve 
and structural interventions, as well as in combination 
with oral anticoagulation, will also be provided. 
Historical background
The hypothesis of an auxiliary effect of clopidogrel on 
top of aspirin in reducing cardiovascular ischaemic 
events rose from the well-established knowledge that 
platelet adhesion and activation occur through many 
different molecular mechanisms [4, 5]. After the intro-
duction of bare metal stents (BMSs) in the early 1990s, 
aspirin was combined with an additional anti-
thrombotic drug, initially ticlopidine, later clopi-
dogrel, to prevent stent thrombosis during the first 
4 weeks after stent implantation [6].
The first data in the BMS era, showing a clinical advan-
tage of extended (>1 month) combination therapy with 
clopidogrel and aspirin in non ST-segment elevation 
ACS, came in 2001 from the CURE trial (Clopidogrel in 
Unstable Angina to prevent Recurrent Events), where 
the prolonged combined treatment led to an absolute 
reduction of 2.1% in risk for the composite endpoint, 
with a benefit maintained over time, particularly in 
the subgroup of patients undergoing percutaneous re-
vascularisation [7, 8]. A similar trend was observed in 
2003 in the CREDO trial, which showed an absolute 3% 
and a relative 27% risk reduction in the cumulative 
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Figure 1: Pathways of platelet activation and their pharmacological targets.
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endpoint when comparing 1 month with 12 months of 
DAPT [9]. 
A few years later (2005–2006), safety issues with first-
generation drug eluting stents (DESs), concerning the 
occurrence of late and very late stent thrombosis related 
to the use of antiproliferative drugs inhibiting complete 
re-endothelialisation for a prolonged time, prompted 
concerns about the optimal length of DAPT [10–13]. 
The CHARISMA trial (Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Manage-
ment and Avoidance) was the first to hypothesise that 
DAPT lasting more than 12 months could provide 
greater protection against recurrent events than aspi-
rin alone [14]. 
More recently, two large ground-breaking trials, TRI-
TON-TIMI 38 and PLATO, tested two new P2Y12 inhibitors, 
prasugrel and ticagrelor, and reassessed the antithrom-
botic approach in patients presenting with ACS [15, 16].
Clinical condition STEMI NSTEMI Stable CAD
Invasive approach
Goal of DAPT
• Hours/Minutes before PCI
  (preloading)
• Months after PCI
• Years after PCI
Emergency PCI
(<90 min)
Lesion preparation
Stent Protection
(9–12 months)
Patient Protection
(in selected cases)
Urgent PCI (24–48 h) Elective PCI
Lesion preparation
Stent Protection
(9–12 months)
Patient Protection
(in selected cases)
Patient Protection
(in selected cases)
Stent Protection
(3–6 months)
thrombus burden +++ thrombus burden ++ No thrombus burden
–
Figure 2: Current open issues in dual antiplatelet therapy.
Table 1: Details of available P2Y12 inhibitors.
Oral administration Intravenous administration
Clopidogrel Prasugre! Ticagrelor Cangrelor
Drug class —  
antiplatelet  
mechanism
Thienopyridine  
P2Y12 inhibitor
Thienopyridine  
P2Y12 inhibitor
Cyclopentyltriazolopyrimidine  
P2Y12 inhibitor
ATP analogue —  
ADP P2Y12 inhibitor
Loading/maintenance  
dose
300–600 mg / 75 mg once daily60 mg / 10 mg once daily 180 mg / 90 mg twice daily 30 pg/kg bolus / 4 pg/kg/min  
infusion
Reversibility Irreversible Irreversible Reversible Reversible
Bio-activation prodrug, variable 
cytochrome P450 
metabolism
prodrug, predictable
cytochrome P450  
metabolism
Active drug Active drug
Onset of action 2–6 hours 30 min. 30 min. 2 min.
Duration of action 3–10 days 7–10 days 3–5 days 1–2 hours
Withdrawal before  
surgery
5 days 7 days 5 days 1 hour
Cost 740 CHF/year 1135 CHF/year 1354 CHF/year Hospital administration only
Available drugs
A summary of currently used P2Y12 inhibitors is avail-
able in table 1.
Clopidogrel
Clopidogrel (300–600 mg loading dose and 75 mg/day 
maintenance dose) is an oral thienopyridine deriva-
tive. Its active metabolite blocks platelet P2Y12 recep-
tors irreversibly, thereby preventing the binding of 
adenosine diphosphate (ADP) and thus counteracting 
ADP-dependent activation of GpIIb-IIIa, the major 
platelet receptor for fibrinogen. As an inactive pro-
drug, clopidogrel requires a two-step oxidation by the 
hepatic cytochrome P450 system (specifically by 
CYP2C19) to generate an active metabolite. This two-
step conversion results in a slower onset of action than 
those of prasugrel and ticagrelor. Furthermore, sub-
stantial interindividual variability in the antiplatelet 
response to this drug has been documented: several 
different alleles of CYP2C19 have been related to re-
duced or increased enzymatic activity of the cy-
tochrome and variable clinical efficacy of clopidogrel.
Prasugrel
Prasugrel (60 mg loading dose and 10 mg/day mainte-
nance dose) is an orally inactive prodrug, also derived 
from thienopyridine, which irreversibly binds and 
thus inhibits P2Y12 receptors on platelets. Prasugrel re-
quires conversion to an active metabolite through a 
one-step cytochrome P450-dependant reaction, ensur-
ing a faster onset of action and a more predictable clin-
ical effect than with clopidogrel. According to the TRI-
TON-TIMI 38 post-hoc analysis data, prasugrel is 
contraindicated in patients with prior stroke (or tran-
sient ischaemic attack), or in patients older than 75 
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years or with low body weight (<60 kg) [2, 3, 14]. The role 
of a reduced 5-mg dose of prasugrel in these subsets of 
patients is currently under investigation.
Ticagrelor
Ticagrelor (180 mg loading dose and 90 mg twice a day 
maintenance dose) is an oral P2Y12 receptor antagonist 
belonging to the chemical class of cyclopentyltriazolo-
pyrimidines [16]. It acts through a double antiplatelet 
mechanism, inhibiting both P2Y12 receptors and aden-
osine reuptake via the equilabrative nucleoside trans-
porter 1 (ENT1). Unlike clopidogrel and prasugrel, tica-
grelor binds reversibly to the P2Y12 receptor, leading to 
a faster offset of action with more rapid recovery of 
platelet function (5 days). Furthermore, ticagrelor is an 
orally active drug requiring no metabolic activation, 
which provides a much faster onset of action and more 
reliable inhibition than clopidogrel. Adverse effects, 
potentially linked to its inhibition of ENT1, include 
dose-related episodes of dyspnoea and bradycardia. To 
date, the only head-to-head comparison data between 
ticagrelor and prasugrel come from the recent, but 
greatly underpowered, Prague 18 trial, which did not 
show any difference between the two potent anti-
thrombotic drugs in term of predefined endpoints at 7 
and 30 days in 1250 “real world” patients with ST-seg-
ment elevation myocardial infaction (STEMI) treated 
with primary PCI [17]. 
Cangrelor
Cangrelor (30 mg/kg bolus and 4 mg/kg/min infusion) 
is an intravenous adenosine triphosphate analogue 
that binds directly and reversibly to the P2Y12 receptor, 
without requiring metabolic activation. It produces re-
versible and highly effective platelet inhibition, with 
an almost immediate onset after administration of the 
intravenous bolus. It has a short plasma half-life (3–6 
min), thus allowing restoration of platelet function 
within 1–2 hours after infusion discontinuation. The 
CHAMPION-PHOENIX trial, comparing cangrelor with 
clopidogrel in an all-comers population with stable 
coronary heart disease and acute coronary syndromes 
[18], failed to demonstrate any convincing and cost ef-
fective advantages of the parenteral drug. Thus, cur-
rent use of cangrelor is limited to a bridge to surgery in 
patients with a high bleeding risk, or as an alternative 
for preloading in ACS patients experiencing nausea 
and vomiting or reduced oral drug absorption due to 
impaired peripheral perfusion. 
Current role of dual antiplatelet therapy
In the following section we will focus on open issues 
about DAPT: the role of preloading in acute coronary 
syndromes, the optimal length of treatment after PCI 
in stable coronary artery disease and ACS, and the role 
of extended DAPT after 12 months in selected patients.
Preloading in acute coronary syndromes
The rationale for P2Y12 receptor blocker administration 
before PCI in ACS arises from the observation that the 
risk of early thrombotic complications, such as re-in-
farction or acute stent thrombosis, is directly related to 
the level of platelet reactivity (fig. 3).
Several issues have to be addressed when considering 
preloading. First, the drug should be administered in a 
timely manner, early enough to allow complete inhibi-
tion at the time of PCI. Secondly, the delay between drug 
administration and its pharmacological action is re-
lated not only to the pharmacokinetics of the molecule, 
but also to some patient-specific clinical conditions (e.g., 
STEMI vs NSTEMI, low cardiac output syndromes, etc.) 
that may further delay absorption. Thirdly, the addition 
of a second antiplatelet agent on top of aspirin obvi-
ously increases the haemorrhagic risk, particularly in 
the subgroup of patients (5–10%) who might benefit 
from accelerated surgical revascularisation.
Given these premises, preloading with a P2Y12 inhibitor 
has been considered a rationally appealing approach, 
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Figure 3: The course of the level of platelet inhibition over time in patients with P2Y12 
pretreatment (green curve) and in patients without pretreatment (red curve). The oppor-
tunity to benefit from pretreatment effect exists within the area with slanted grey lines, 
the area between the red and green curves. The risk of stent thrombosis (black curve) is 
highest during and in the early period after percutaneous coronary intervention, with a 
subsequent decline in risk thereafter. Following a loading dose with P2Y12 inhibitors, the 
maximum level of platelet inhibition is usually seen within hours and up to the day after 
percutaneous coronary intervention, with a minor decline in inhibition during mainte-
nance therapy before reaching a steady-state level. From: Sibbing D, Kastrati A, Berger 
PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which 
agent? Eur Heart J. 2016;37(16):1284–95. Reprinted with permission.
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particularly in an era where clopidogrel, with its slow 
onset of action, was the first and the only available 
P2Y12 inhibitor.
ST-segment elevation ACS
ST-segment elevation myocardial infarction (STEMI) is 
characterised by strong platelet hyper-reactivity and 
the need to achieve vessel reperfusion within 90 min-
utes from symptom onset, clearly requiring fast and 
adequate platelet inhibition. In this context, the syner-
gic action of heparin, aspirin and ADP receptor antago-
nists aims to reduce thrombotic activity at the site of 
plaque rupture and to minimise the thrombogenic im-
pact of the percutaneous intervention.
The indications in guidelines have changed considera-
bly over time, because of the introduction of newer 
drugs and of contrasting evidence on pretreatment in 
STEMI patients. Initial experience and, consequently, 
guidelines were strongly in favour of preloading [19, 
20], but newer data challenged this concept [21, 22].
In particular, the recent ATLANTIC trial, the only avail-
able randomised study comparing out-of-hospital pre-
loading with administration at the time of PCI in 
STEMI, failed to show any benefit of the upstream pre-
treatment in terms of coronary reperfusion and out-
come at 30 days, nevertheless with a small but signifi-
cant reduction of definite stent thrombosis up to 30 
days [21]. Even though the 2014 European society of 
Cardiology (ESC) guidelines on coronary revascularisa-
tion still recommend preloading in STEMI [2], recent 
evidence derived from the ATLANTIC trial weakened 
the concept of preloading in STEMI and will probably 
lead to future modifications of recommendations.
Non-ST-segment elevation-ACS
In contrast to STEMI, the therapeutic goal of an-
tithrombotic treatment in the setting of non-ST-seg-
ment elevation-ACS (NSTEMI) is to stabilise the coro-
nary plaque in view of mechanical revascularisation, 
which should take place within 24 to 48 hours [3]. 
Whereas previous guidelines warmly recommended 
preloading with a P2Y12 inhibitor upstream [20], the 
only trial testing this hypothesis failed to demonstrate 
any advantage. In fact, the ACCOAST trial, published in 
2013, which compared pretreatment with 30 mg of 
prasugrel (and a further 30 mg dose at the time of PCI) 
with prasugrel 60 mg given after diagnostic angiogra-
phy, did not show any benefit in terms of cardiovascu-
lar death, recurrent myocardial infarction, stroke, ur-
gent revascularisation and bailout use of GPIIb/IIIa 
inhibitors at 7 and 30 days. Instead, a significant in-
crease in major bleedings in the pretreated group was 
observed [22]. 
Uncertainties about preloading are mirrored in the 
2015 edition of the ESC NSTEMI guidelines, which 
clearly discourage pretreatment with prasugrel, and 
give no recommendation favouring or discouraging 
the use of clopidogrel or ticagrelor, clearly highlighting 
the lack of evidence to support either strategy [3].
A summary of the current recommendation is given in 
table 2.
Optimal length of DAPT after stent  implantation
Current guidelines recommend routine use of DAPT 
for 6 months after DES implantation in stable patients 
and for 1 year after an ACS [2]. 
Several trials evaluated the hypothesis that a shorter 
duration of DAPT would guarantee good efficacy and 
safety after newer-generation stent implantation [23-
27], and tested various regimens of DAPT differing in 
terms of drugs used or length of treatment. Pooled 
data from these trials, including more than 30 000 pa-
tients, concluded that a short course of antithrombotic 
treatment lasting 3–6 months provides a similar safety 
profile to longer treatment (12 months) (table 3) [28]. 
Regardless of different therapeutic options and guide-
line recommendations, the current trend is to shorten 
DAPT to the minimum period required according to pa-
tient and stent characteristics. So far, this approach has 
Table 2: Current recommendations on pretreatment in STEMI and NSTEMI patients. 
Modified from: Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors  
in ACS patients: who, when, why, and which agent? Eur Heart J. 2016;37(16):1284–95. 
Reprinted with permission.
STEMI
Routine pre-hospital pretreatment cannot be recommended for patients with STEMI 
over the in-lab administration of the drug since the two strategies had similar outcomes.
It can be advisable to administer potent and rapidly acting antiplatelet agents (prasugrel 
or ticagrelor) in the emergency department (i.e., ambulance) once the diagnosis of 
STEMI is confirmed and the patient proceeds to primary PCI.
NSTEMI
It is advisable to administer a potent and rapidly acting antiplatelet agent (prasugrel or 
ticagrelor) once the coronary anatomy is known (and the patient proceeds to immediate 
PCI).
If prasugrel or ticagrelor are contraindicated, pretreatment with clopidogrel before co-
ronary angiography may be advisable for patients with low bleeding risk and a high 
likelihood for immediate PCI, especially if radial access is planned.
Table 3: Adverse events according to the length of treatment.
DAPT  
3–6 months
DAPT  
12 months
RR 
ST* rate (%) 0.5 0.4 0.1
Pooled MI+ (%) 1.7 1.5 0.2
Major bleeding (%) 0.4 0.8 0.4
Death rate (%) 1.7 1.9 0.2
*ST: stent thrombosis; +MI: Myocardial infarction;
Pooled data derived from ISAR SAFE, ITALIC, SECURITY, OPTIMIZE, 
PRODIGY, RESET and EXCELLENT trials. Modified from G. Montalescot 
et al. J Am Coll Cardiol. 2015;66:832–47
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been evaluated in the RESET [25] and OPTIMIZE (26) tri-
als, which compared 3 and 12 months DAPT after im-
plantation of a zotarolimus-eluting stent in patients 
with stable coronary artery disease. Both studies dem-
onstrated noninferiority of the shorter treatment for 
the composite endpoint of all-cause death, myocardial 
infarction, stroke or major bleeding [26], as well as stent 
thrombosis and target vessel revascularisation [25]. 
In patients at high bleeding risk, the predefined DAPT 
period can be further shortened to 4 weeks when poly-
mer-free drug-eluting stents are used. This is sup-
ported by evidence derived from the recent LEADERS 
FREE trial, which showed similar safety and superior 
efficacy with these stents as compared with conven-
tional BMSs [29].
Factors that need to be considered in estimating bleed-
ing (favouring shorter DAPT) and ischaemic risk (fa-
vouring longer DAPT) are listed in table 4.
DAPT beyond 12 months
Several studies [14, 24, 30–34] hypothesised that pro-
longed platelet inhibition might result in a better pro-
tection against recurrent cardiovascular events.
The first study evaluating this strategy, the CHARISMA 
trial (with more than 15 000 patients at risk of, or with 
established, cardiovascular diseases randomised to ei-
ther aspirin alone or a combination of aspirin plus 
clopidogrel for a median of 28 months) failed to demon-
strate any advantage of prolonged DAPT but raised 
some safety concerns in terms of bleeding [14]. A few 
years later, the DES-LATE study also failed to show any 
benefit associated with clopidogrel plus aspirin vs of as-
pirin alone in reducing the incidence of myocardial in-
farction or death from cardiac causes at 12 months [32]. 
More recently, the large Dual Antiplatelet Therapy 
(DAPT) study, compared the extension of DAPT up to 
30 months after PCI vs the conventional approach in 
almost 10 000 event-free patients (30). Prolonged treat-
ment after PCI significantly reduced the rates of stent 
thrombosis, myocardial infarction and major adverse 
cardiovascular events. Notably, the reduction in myo-
cardial infarction was significant in both target and 
non-target lesions, suggesting a secondary prevention 
effect of long-term DAPT. However, in line with previ-
ous studies, a safety concern was raised owing to the 
increase in moderate to severe bleeding, all-cause mor-
tality and deaths for non-cardiovascular causes in the 
treatment group. 
Finally, the recent PEGASUS-TIMI 54 study, evaluating 
two different doses of ticagrelor (90 or 60 mg twice 
daily) plus aspirin vs aspirin alone in more than 21 000 
stable high-risk patients (myocardial infarction 1–3 
years earlier) with a median follow-up to 33 months, 
was reported [33]. Consistently with the previous ob-
servations, the study demonstrated a significant re-
duction in terms of the primary efficacy endpoint 
(combined death, reinfarction, stroke after 3 years). 
However, an increased risk of major bleeding for the 
two ticagrelor doses was also observed (2.6% for tica-
grelor 90 mg vs 2.3% for ticagrelor 60 mg vs 1.0% for as-
pirin alone). 
A summary of current evidence is available from an el-
egant meta-analysis, published in 2015 [35], which 
clearly showed that DAPT maintained well beyond 12 
months (up to 24–30 months) reduces the incidence of 
thrombotic complications, in particular stent throm-
bosis and myocardial infarction, at the price of an in-
crease in major bleeding and possibly in all-cause mor-
tality.  In other words, the dichotomy between efficacy 
and safety still represents the Achille’s heel of this ap-
pealing, but challenging approach. 
In conclusion, although 2014 ESC guidelines on myo-
cardial revascularisation do not recommend routine 
extension of DAPT, on the other hand and in the light 
of the more recent results of the DAPT and Pegasus tri-
Table 4: Characteristics related to increased ischaemic/
bleeding risk.
Increased ischaemic risk or risk of stent thrombosis  
(may favour longer-duration DAPT)
Recurrent ischaemic episode on DAPT
ACS presentation in young patients
LV dysfunction
High vascular burden
Chronic stable kidney disease
Additional stent factors
First-generation DES
Stent undersizing
Bifurcation stent
Stent-in-stent
Increased bleeding risk  
(may favor shorter-duration DAPT)
Very old patients
Short life expectancy
Poor DAPT adherence
End-stage renal failure
Malignancy
Short term candidates for high risk surgery
Severe anaemia
History of prior bleeding
Major haematological disorders
Oral anticoagulation
Low body weight
*Modified from Levine GL et al ACC/AHAGuidelines Focused Update on 
Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery 
Disease
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als, treatment for more than 12 months can be consid-
ered in selected patients with a very high ischaemic 
burden (e.g., severe coronary artery disease in young 
patients with multiple risk factors, recurrent events) 
and at a very low bleeding risk
DAPT and oral anticoagulation
Almost 6–8% of patients undergoing PCI have an indi-
cation for chronic oral anticoagulation (OAC) with vi-
tamin K antagonists (VKAs) or new oral anticoagu-
lants (NOACs), as a result of various conditions such as 
atrial fibrillation, mechanical heart valves and recent 
or recurrent venous thromboembolism. However, 
adding antiplatelet agents to warfarin increases non-
fatal and fatal bleeding risk more than 3-fold as com-
pared with DAPT [36]. Therefore, clinical judgment 
and regular reassessment of the indication for OAC is 
essential. 
Current guideline recommendations, derived from 
large registries [36], from rather small and underpow-
ered randomised trials [37, 38] and from post-hoc anal-
yses of the large randomised trials on atrial fibrilla-
tion, still recommend a pragmatic approach mainly 
based on a clear distinction between stable and acute 
coronary syndromes and on balancing the systemic 
bleeding risk by use of validated risk scores [3]. In pa-
tients with an acute coronary event and low bleeding 
risk (HAS-BLED score ≤2) extension of the triple ther-
apy, consisting of aspirin, clopidogrel and either a vita-
min K antagonist or NOAC, up to 6 months is recom-
mended. In patients with stable coronary artery 
disease but at a high haemorrhagic risk (HAS-BLED 
score >2), a shortened triple therapy (1–3 months) and 
then a switch to a combination of one antiplatelet drug 
(either aspirin or clopidogrel) and one oral anticoagu-
lant for up to 12 months is advised.
In accordance with a joint consensus document [39], and 
in line with the most recent European Guidelines on 
atrial fibrillation [40], discontinuation of any antiplate-
let agent at 1 year is encouraged irrespective of stent 
type, whereas dual therapy with oral anticoagulation 
and one antiplatelet agent (aspirin or clopidogrel) may 
be considered in very selected patients at high risk of re-
current ischaemic events. Prasugrel or ticagrelor as part 
of triple therapy should be avoided, since these potent 
P2Y12 receptor inhibitors generate an unpredictable risk 
of fatal bleeding. In addition, when VKAs are used, the 
prothrombin time international normalised ratio (INR) 
should be carefully maintained within a target of 2.0–
2.5. In patients treated with NOACs, the lowest tested 
dose for stroke prevention should be applied (e.g., rivar-
oxaban 15 mg once daily). 
The appropriate role of NOACs was investigated in the 
hypothesis-generating PIONEER AF-PCI [42], which en-
rolled 2124 patients with non-valvular atrial fibrilla-
tion who had undergone PCI. Patients were randomly 
assigned to receive low-dose rivaroxaban (15 mg once 
daily) plus a P2Y12 inhibitor for 12 months, very-low-
dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6 
or 12 months, or standard therapy with a dose-adjusted 
VKA (once daily) plus DAPT for 1, 6 or 12 months. De-
spite its complexity, the study showed a clear benefit in 
terms of bleeding rates and similar safety for the two 
rivaroxaban groups as compared with the standard 
treatment. Even though the trial was not powered to 
evaluate efficacy, it definitely opens new perspectives 
in this increasingly important area of antithrombotic 
treatment.
Open questions and future perspectives
One of the future directions being currently investi-
gated is the potential role of a single antiplatelet treat-
ment with one of the novel potent antithrombotic 
drugs as an alternative to the conventional DAPT ap-
proach. 
The ongoing Global LEADERS trial, with more than 
16 000 patients included and a 2-year follow up, aims to 
evaluate whether, after an initial short (1-month) DAPT 
period, ticagrelor monotherapy will provide similar 
antithrombotic efficacy without increasing the long-
term risk of bleeding [43]. If this trial succeeds in dem-
onstrating this, it could have a revolutionary impact 
on the clinical management of patients with ischaemic 
heart disease. 
Moreover, the currently ongoing, large-scale COMPASS 
trial, which includes more than 20 000 patients with 
documented atherosclerosis, is currently investigating 
the role of a low dose factor X inhibitor (rivaroxaban 
2.5 mg twide daily + aspirin vs rivaroxaban 5 mg twice 
daily alone vs aspirin alone) in protecting against fu-
ture cardiovascular events. Also in this case, if efficacy 
were proven, this would represent an important game-
changer in the immediate future [44]. 
In other words, the antithrombotic perspective could 
considerably change in the coming years, according to 
the results of ongoing trials. 
Platelet inhibition following structural 
 interventions
The rationale behind platelet inhibition following 
structural interventions such as transcatheter aortic 
valve implantation (TAVI), transcatheter edge-to-edge 
mitral valve repair, left atrial appendage occlusion or 
patent foramen ovale / atrial septal defect occlusion is 
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represented by both the need to prevent early throm-
bosis due to the loss of integrity of the endothelium at 
the time of the procedure and the need to prevent de-
vice thrombosis until complete endothelialisation is 
achieved.
Although there is a general consensus among cardiolo-
gists on the need for platelet inhibition, multiple em-
pirical approaches are adopted in clinical practice. In 
the absence of clinical trials evaluating alternate anti-
thrombotic regimens, especially after TAVI, no consen-
sus on the optimal agent(s) or duration of therapy is yet 
available [45].
The recent WRITTEN survey highlighted that DAPT was 
the most common antithrombotic treatment pre-
scribed at hospital discharge after TAVI. Nonetheless, 
significant differences were observed in terms of dura-
tion, this varying from 1 month in 14.3%, 3 months in 
43.8%, 6 months in 35.5%, 12 months in 4.6% and indefi-
nitely in 0.5% centres, while only a minority reported 
systematic use of single antiplatelet therapy with 
 aspirin alone [46]. Even though some authors [47, 48] 
questioned the need for DAPT, we strongly support the 
current recommendation to consider DAPT for a mini-
mum period of 1 to 3 months, as long as data from a 
large randomised trial are not available. 
The concomitant presence of atrial fibrillation or alter-
native indications for oral anticoagulation clearly add 
complexity to complexity, and in fact it is not yet clear 
whether platelet inhibition is needed in the presence 
of oral anticoagulation. 
The introduction of NOACs also opened new possibili-
ties in patients undergoing TAVI. The currently run-
ning phase III GALILEO study, in which approximately 
1 500 TAVI patients with no previous indication for 
OAC were randomly allocated to either rivaroxaban 10 
mg plus aspirin once daily for 3 months followed by ri-
varoxaban 10 mg alone, or to standard DAPT with 
clopidogrel on top of aspirin for 3 months followed by 
aspirin alone, will most probably add new information 
and most probably impact on the current practice [49].
Concerning use and length of the dual antiplatelet 
therapy in the clinical context of structural interven-
tions such as patent foramen ovale, atrial septal defect 
and left atrial appendage closure or after percutaneous 
mitral valve repair, the medical evidence is even more 
scanty and the current practice is still based on empiri-
cal recommendations which suggest combining aspi-
rin with clopidogrel for up to 3 months followed by as-
pirin (or clopidogrel) alone for up to 6 months or as 
long as required by the clinical condition.
Conclusions
Dual antiplatelet treatment in the clinical context of 
coronary stent implantation is an evolving area with 
rapidly changing medical evidence and recommenda-
tions. On the basis of recent negative trials, preloading 
in ACS has been definitely called into question; con-
cerning post-stent DAPT therapy, the current trend is 
to shorten treatment to the minimum required period 
and to stratify the approach according to patient and 
stent characteristics; finally, long term treatment for 
more than 12 months should only be considered in 
highly selected cases with a high ischaemic burden 
and a predicted low bleeding risk.
Ongoing large trials are currently investigating the 
role of single antiplatelet therapy with the new P2Y12 
inhibitors and the potential use of new oral anticoagu-
lants both in the setting of coronary artery disease and 
as an adjunctive therapy after structural interven-
tions.
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